Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:PHAR's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.895
vs CAI:PHAR: -10.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Egyptian International Pharmaceutical Investments (CAI:PHAR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Egyptian International Pharmaceutical Investments's PE Ratio (TTM) for today is calculated as:
Egyptian International Pharmaceutical Investments's share price for today is E£86.47.
Egyptian International Pharmaceutical Investments's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£6.591.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Egyptian International Pharmaceutical Investments EV-to-FCF Related Terms
Egyptian International Pharmaceutical Investments EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments EV-to-FCF Chart
Egyptian International Pharmaceutical Investments Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments EV-to-FCF vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments's current Enterprise Value is E£23,662 Mil.
Egyptian International Pharmaceutical Investments's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-2,270 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a EV-to-FCF of -10.43 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Egyptian International Pharmaceutical Investments and its competitors. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is Egyptian International Pharmaceutical Investments' EV-to-FCF too high?
Egyptian International Pharmaceutical Investments' current EV-to-FCF is -10.43. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #999999 out of 564 companies for EV-to-FCF. This places Egyptian International Pharmaceutical Investments in the lower half of its industry. The industry median EV-to-FCF is 20.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.90, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current EV-to-FCF is -10.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.82, compared to a current price of E£86.47 — trading 44.6% above its estimated fair value. The current EV-to-FCF is -10.43. Egyptian International Pharmaceutical Investments' overall GF Score™ is 70/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current EV-to-FCF is -10.43 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£86.47 is trading 44.6% above its estimated GF Value™ of E£59.82.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
EV-to-FCF: -10.43
GF Value™: E£59.82 vs. price of E£86.47 (44.6% above fair value)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
70GF Score
Get the complete analysis for CAI:PHAR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
